After a slow start, generic pharmaceutical companies now accelerate their use of inter partes review patent challenges

Expert article by Joseph E. Cwik on April 29, 2014. Originally published on Healthcare Law Insights, reposted with the permission of Joseph E. Cwik. When inter partes review actions first became available in 2012, no generic pharma companies availed themselves to this litigation tool. Not until 2013 did a generic pharma company first seek inter…

Husch Blackwell leads the charge in first inter partes review wins against pharmaceutical-related patents

Expert article by Joseph E. Cwik and Josh Nosal on July 2, 2014. Originally published on Healthcare Law Insights, reposted with the permission of Joseph E. Cwik. The Patent Trial and Appeal Board (PTAB) issued its first final written decisions June 20, 2014, in four inter partes reviews (IPR) of pharmaceutical-related patents. The four decisions…